A parallel, randomized, controlled phase III clinical trial comparing the efficacy and safety of regorafenib and furquintinib in the third line treatment of colorectal cancer
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2700735
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Regorafenib group:Regorafenib;Furquitinib group:Furquitinib
Primary outcome(s): Progression free survival
Study Design: Parallel
创建时间：
2020-12-15
